Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024;18(7):333-344.
doi: 10.2217/bmm-2023-0727. Epub 2024 May 3.

Prognostic value of PD-L1 expression in patients with anal cancer: a meta-analysis

Siqi Gong  1 , Jiafeng Song  1
Affiliations
Meta-Analysis

Prognostic value of PD-L1 expression in patients with anal cancer: a meta-analysis

Siqi Gong et al. Biomark Med. 2024.

Abstract

Background: The present meta-analysis was performed to evaluate the prognostic and clinicopathological significance of PD-L1 in anal cancer (AC). Methods: Hazard ratios (HRs) and 95% CIs regarding overall survival (OS) and progression-free survival (PFS) were calculated based on PD-L1 levels. Results: According to the combined data, PD-L1 showed no significant relationship with OS (HR = 0.76; 95% CI = 0.35-1.67; p = 0.502) or PFS (HR = 0.88; 95% CI = 0.35-2.33; p = 0.789) in patients with AC. Based on subgroup analysis, PD-L1 overexpression significantly predicted prolonged OS (HR = 0.38; 95% CI = 0.17-0.84; p = 0.017) in tumor node metastasis stages I-III and inferior PFS (HR = 2.73; 95% CI = 1.32-5.65; p = 0.007) in patients with stage I-IV AC. Conclusion: PD-L1 level assessed by immunohistochemistry did not significantly predict survival outcomes in AC cases.

Keywords: PD-L1; anal cancer; clinical practice • meta-analysis; prognosis.

Plain language summary

[Box: see text].

PubMed Disclaimer

Conflict of interest statement

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, stock ownership or options and expert testimony.

Figures

Figure 1.
Figure 1.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart.
Figure 2.
Figure 2.
Forest plots of prognostic role of PD-L1 for overall survival in patients with anal cancer.
Figure 3.
Figure 3.
Forest plots of prognostic role of PD-L1 for progression-free survival in patients with anal cancer.
Figure 4
Figure 4
Forest plots of associations between PD-L1 and clinicopathological factors in anal cancer. (A) HPV p16 status (positive vs negative). (B) Sex (female vs male). (C) Tumor node metastasis stage (III–IV vs I–II). (D) Histological grade (poor vs well/moderate).
Figure 4
Figure 4
Forest plots of associations between PD-L1 and clinicopathological factors in anal cancer. (A) HPV p16 status (positive vs negative). (B) Sex (female vs male). (C) Tumor node metastasis stage (III–IV vs I–II). (D) Histological grade (poor vs well/moderate).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Gondal TA, Chaudhary N, Bajwa H, Rauf A, Le D, Ahmed S. Anal cancer: the past, present and future. Curr. Oncol. (Toronto) 30(3), 3232–3250 (2023). - PMC - PubMed
    1. Sung H, Ferlay J, Siegel RLet al. . Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021). - PubMed
    1. Hoff PM, Coudry R, Moniz CM. Pathology of anal cancer. Surg. Oncol. Clin. North Am. 26(1), 57–71 (2017). - PubMed
    1. Daling JR, Madeleine MM, Johnson LGet al. . Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 101(2), 270–280 (2004). - PubMed
    1. Giunta EF, Bregni G, Hendlisz A, Sclafani F. Anal squamous cell carcinoma: standards of care, new data and ongoing clinical trials. Curr. Opin. Oncol. 33(4), 372–377 (2021). - PubMed

Publication types

LinkOut - more resources